211 related articles for article (PubMed ID: 30787326)
21. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
22. ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Iseda N; Itoh S; Yoshizumi T; Yugawa K; Morinaga A; Tomiyama T; Toshima T; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Apr; 5(4):675-688. PubMed ID: 33860125
[TBL] [Abstract][Full Text] [Related]
23. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
[TBL] [Abstract][Full Text] [Related]
25. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
26. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
29. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
30. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.
Wang H; Tan M; Zhang S; Li X; Gao J; Zhang D; Hao Y; Gao S; Liu J; Lin B
Int J Mol Sci; 2015 Feb; 16(2):3391-404. PubMed ID: 25658794
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
32. Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.
Aman M; Ohishi Y; Imamura H; Shinozaki T; Yasutake N; Kato K; Oda Y
Hum Pathol; 2017 Jun; 64():156-163. PubMed ID: 28438620
[TBL] [Abstract][Full Text] [Related]
33. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.
Zhou W; Liu H; Yuan Z; Zundell J; Towers M; Lin J; Lombardi S; Nie H; Murphy B; Yang T; Wang C; Liao L; Goldman AR; Kannan T; Kossenkov AV; Drapkin R; Montaner LJ; Claiborne DT; Zhang N; Wu S; Zhang R
Cancer Cell; 2023 Apr; 41(4):740-756.e10. PubMed ID: 36963401
[TBL] [Abstract][Full Text] [Related]
34. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
Iramaneerat K; Rattanatunyong P; Khemapech N; Triratanachat S; Mutirangura A
Int J Gynecol Cancer; 2011 Jan; 21(1):51-7. PubMed ID: 21330831
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
[TBL] [Abstract][Full Text] [Related]
36. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.
Itamochi H; Oumi N; Oishi T; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Clin Oncol; 2015 Oct; 20(5):967-73. PubMed ID: 25744580
[TBL] [Abstract][Full Text] [Related]
37. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
[TBL] [Abstract][Full Text] [Related]
38. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
39. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.
Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138
[TBL] [Abstract][Full Text] [Related]
40. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.
Zhang X; Zhang Y; Yang Y; Niu M; Sun S; Ji H; Ma Y; Yao G; Jiang Y; Shan M; Zhang G; Pang D
Cancer Epidemiol; 2012 Jun; 36(3):288-93. PubMed ID: 21889920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
